


## Thalidomide-O-amido-C6-NH2 TFA

## Chemical Properties

|                   |  |
|-------------------|--|
| CAS No. :         | 1950635-14-9   |
| Formula:          | C46H53F6N8O16  |
| Molecular Weight: | 1087.95  |
| Storage:          | Keep away from direct sunlight<br>Powder: -20°C for 3 years   In solvent: -80°C for 1 year<br><i>Actual storage temperature shall be subject to the COA.</i> |



## Biological Description

|               |   |
|---------------|---|
| Description   | Thalidomide-O-amido-C6-NH2 TFA (Cereblon Ligand-Linker Conjugates 11 TFA) is a synthesized E3 ligase ligand-linker conjugate comprising a Thalidomide-based cereblon ligand and a linker.   |
| Targets(IC50) | Apoptosis, Autophagy, E3 Ligase Ligand-Linker Conjugates, Ligands for E3 Ligase, PROTAC Linker  |
| In vitro      | PROTACs consist of two ligands connected by a linker, one targeting an E3 ubiquitin ligase and the other targeting the protein of interest. They leverage the intracellular ubiquitin-proteasome system to selectively degrade target proteins [1]. |

## Solubility Information

|                     |  |
|---------------------|--|
| Solubility          | DMSO: 105.5 mg/mL (96.97 mM), Sonication is recommended.<br>(< 1 mg/ml refers to the product slightly soluble or insoluble)  |
| In vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (4.6 mM), Sonication is recommended.<br><i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i> |

### Preparing Stock Solutions

---

|       | 1mg       | 5mg       | 10mg      |
|-------|-----------|-----------|-----------|
| 1 mM  | 0.9192 mL | 4.5958 mL | 9.1916 mL |
| 5 mM  | 0.1838 mL | 0.9192 mL | 1.8383 mL |
| 10 mM | 0.0919 mL | 0.4596 mL | 0.9192 mL |
| 50 mM | 0.0184 mL | 0.0919 mL | 0.1838 mL |

---

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Bradner J, et al. Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses. WO 2017024318 A1

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481